Study | study type
|
Pathology | T1 | T0 | Patients | sample sizes | ROB | Results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
versus Standard of Care (SoC) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
veliparib plus paclitaxel plus carboplatin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BrighTNess (velaparib-P-C (arm A) vs paclitaxel - carboplatin (arm B)), 2018 NCT02032277 | RCT | mBC - TNBC - L1 - all population | veliparib plus paclitaxel plus carboplatin | placebo plus paclitaxel plus carboplatin | Patients: women who had histologically or cytologically confirmed invasive TNBC, clinical stage II-III | 316 / 160 | NA | inconclusive |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 2018 NCT02032277 | RCT | mBC - TNBC - L1 - all population | veliparib plus paclitaxel plus carboplatin | placebo matching veliparib plus placebo matching carboplatin plus paclitaxel | Patients: women who had histologically or cytologically confirmed invasive TNBC, clinical stage II-III | 316 / 158 | NA | conclusif |
|